Publications by authors named "Mahtab Sheikh"
Article Synopsis
- - Alzheimer's disease (AD) mainly impacts people aged 65 and older, leading to gradual cognitive and functional decline that disrupts daily activities.
- - The disease is characterized by the presence of amyloid plaques that damage neurons and brain connections, and until 2023, treatments only addressed symptoms without altering the disease's progression.
- - In 2023, the FDA approved Lecanemab and aducanumab, marking the first therapies with the potential to modify the disease, with Lecanemab showing promise in improving cognitive function in patients.
